---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-021527"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2023-02-01T23:59:59+00:00"
generated_at: "2026-06-20T04:05:50.183190+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics reports preliminary cash of $114.7M as of Dec 31, 2022

## Summary
- Preliminary unaudited cash, cash equivalents and marketable securities total approximately $114.7 million at Dec 31, 2022.
- Quarter-end financial close for Q4 2022 is not yet complete; figure is subject to change upon finalization.
- No additional financial results, revenue, or earnings data were provided in this filing.
- The cash balance excludes any subsequent financing or operating activities through the filing date.

## SEC filing metadata
- accession: 0001193125-23-021527
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2023-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312523021527/0001193125-23-021527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312523021527/d413444d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-021527
- JSON: https://secwatch.observer/filing/0001193125-23-021527.json
- Plain text: https://secwatch.observer/filing/0001193125-23-021527.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.